John H. Heiligenstein

Author

Also Known As

J H Heiligenstein, J HEILIGENSTEIN, J Heiligenstein, J. H. Heiligenstein, J. Heiligenstein, J.H. Heiligenstein, JOHN H. HEILIGENSTEIN, John H Heiligenstein, John H. Heiligenstein, John Heiligenstein

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Massachusetts General Hospital The University of Texas Southwestern Medical Center University of Nebraska Medical Center Harvard University Press

About

John H. Heiligenstein is an author at Eli Lilly (United States) specializing in psychiatry, medicine, and psychopathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	2.6K
2	Social Sciences	14	15	2.1K
3	Health Sciences	1	1	53
4	Management	1	1	18
5	Behavioral Sciences	1	1	11

John H. Heiligenstein

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial Graham J. Emslie, John H. Heiligenstein, Karen Dineen Wagner, Journal of the American Academy of Child & Adolescent Psychiatry Acute TreatmentRandomized Clinical TrialPsychiatryPsychotropic MedicationPediatrics	2002	574
Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder Thomas Spencer, John H. Heiligenstein, Joseph Biederman, The Journal of Clinical Psychiatry	2002	336
Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial Daniel Geller, S. Hoog, John H. Heiligenstein, Journal of the American Academy of Child & Adolescent Psychiatry PsychiatryMedicinePsychotropic MedicationObsessive-compulsive DisorderPediatrics	2001	321
Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label Trial Christopher J. Kratochvil, John H. Heiligenstein, Thomas Spencer, Journal of the American Academy of Child & Adolescent Psychiatry Open-label TrialAdhdPsychiatryPsychotropic MedicationPediatrics	2002	294
Recovery from depression, work productivity, and health care costs among primary care patients Dennis A. Revicki, John H. Heiligenstein, Louis C. Grothaus, General Hospital Psychiatry Family MedicinePrimary CareHealth EconomicsPsychiatryMood Symptom	2000	268
Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial Regina Dittmann, D.S. Fouche, Christopher J. Kratochvil, European Neuropsychopharmacology Open-label TrialAdhdPsychiatryPsychotropic MedicationPediatrics	2001	223
Validation of the ADHD Rating Scale as a clirlician administered and scored instrument Douglas E. Faries, Ilker Yalcin, Donald Harder, Journal of Attention Disorders Psychiatric EvaluationAdhd SymptomsPsychometricsSocial SciencesAdhd	2001	184
A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer Jimmie C. Holland, Steven J. Romano, John H. Heiligenstein, Psycho-Oncology	1998	165
An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder Thomas Spencer, Joseph Biederman, John H. Heiligenstein, Journal of Child and Adolescent Psychopharmacology	2001	150
Fluoxetine Treatment for Prevention of Relapse of Depression in Children and Adolescents: A Double-Blind, Placebo-Controlled Study Graham J. Emslie, John H. Heiligenstein, S. Hoog, Journal of the American Academy of Child & Adolescent Psychiatry PsychiatryAdolescent MedicinePsychotropic MedicationPediatricsDepression	2004	147

Page 1